Beacon Capital Management LLC (Tennessee)’s Vertex Pharmaceuticals VRTX Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150	Closed	-$66.8K	–	995
2025 Q2	$66.8K	Sell	150 -31	-17%	-$14.3K	0.01%	280
2025 Q1	$87.8K	Buy	181 +31	+21%	+$14.4K	0.01%	222
2024 Q4	$60.4K	Hold	150	–	–	0.01%	272
2024 Q3	$69.8K	Buy	150 +7	+5%	+$3.36K	0.01%	262
2024 Q2	$67K	Hold	143	–	–	0.01%	240
2024 Q1	$59.8K	Sell	143 -1	-0.7%	-$423	0.01%	260
2023 Q4	$50.1K	Buy	144 +143	+14,300%	+$52.8K	0.01%	222
2023 Q3	$352	Hold	1	–	–	﹤0.01%	980
2023 Q2	$352	Hold	1	–	–	﹤0.01%	980
2023 Q1	$315	Hold	1	–	–	﹤0.01%	903
2022 Q4	$289	Hold	1	–	–	﹤0.01%	960
2022 Q3	$0	Hold	1	–	–	﹤0.01%	983
2022 Q2	$0	Hold	1	–	–	﹤0.01%	963
2022 Q1	$0	Buy	+1	New	+$237	﹤0.01%	963

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s VRTX Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 150 shares — an estimated $66.8K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in VRTX in Q1 2022 and held it in 14 quarters. The position peaked at $87.8K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 150 Vertex Pharmaceuticals shares in Q3 2025, an estimated $66.8K.
Beacon Capital Management LLC (Tennessee) first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Beacon Capital Management LLC (Tennessee)'s Vertex Pharmaceuticals position peaked at $87.8K in Q1 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.